

RECEIVED


FEB 26 2003

TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on February 12, 2003.

BOX SEQUENCE  
SUBMISSION OF SEQUENCE LISTING  
Examining Group 1644  
Patent Application  
Docket No. SPO-103  
Serial No. 09/142,524

*Frank C. Eisenschenk*



Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Marianne DiBrino  
Art Unit : 1644  
Applicants : Toshio Sone, Akinori Kume, Kazuo Dairiki, Akiko Iwama, Kohsuke Kino  
Serial No. : 09/142,524  
Filed : September 9, 1998  
Conf. No. : 2300  
For : Peptide-Based Immunotherapeutic Agent for Treating Allergic Diseases

SUBMISSION OF SUBSTITUTE SEQUENCE LISTING  
UNDER 37 C.F.R. §§ 1.821-1.825

Sir:

Transmitted herewith is a paper copy of Substitute Sequence Listing under 37 C.F.R. §§ 1.821 through 1.825 for the above-identified patent application that was delivered to the United States Patent and Trademark Office on February 4, 2003 via courier. The computer readable form of the paper copy of the sequence listing for this application has been filed via the electronic filing system (EFS) on this same date and has been accorded EFS ID: 23108 (see attached receipt acknowledging the sequence listing submission [time stamped Feb. 12 09:03:54 EST 2003]). Also enclosed is an Amendment Under 37 C.F.R. § 1.825(a) through (c).

The sequence listing is submitted in computer readable format and on paper. I hereby certify that the paper and computer readable copies contain the same information and that no new material is added by this submission.

The undersigned has also attached copies of all documents delivered to the Patent Office on February 4, 2003, including confirmation of delivery to the Group 1600 receptionist. These documents were related to the submission of a substitute sequence listing in this matter. The sequence submission of February 4, 2003 and the sequence submission of this date are identical in both paper and CRF forms.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Telephone No.: (352) 375-8100

Facsimile No.: (352) 372-5800

Address : Saliwanchik, Lloyd & Saliwanchik  
A Professional Association  
2431 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

FCE/jaj

Attachments: Copy of Amendment Under 37 C.F.R. § 1.825(a)-(c)  
Acknowledgment Receipt for BIO Sequence Filing  
Copy of Substitute Sequence Listing on Paper (pages 1-54)  
Copies of Papers filed February 4, 2003

## Acknowledgment Receipt

SUBMISSION TYPE: BIO Sequence Filing

APPLICATION NUMBER: 09142524

FIRST NAMED INVENTOR: Sone Toshio

TITLE OF INVENTION: Peptide-Based Immunotherapeutic Agent for  
Treating Allergic Diseases

ATTORNEY DOCKET NUMBER: SPO-103

FILE LISTING:

transmittal	transSPO-103.xml 7023 Bytes
sequence-listing	SPO-103.ST25.txt 54354 Bytes
biotechnology-listing-filing	SPO-103bio.xml 1085 Bytes
biotechnology-listing-filing	u-bio.dtd 3619 Bytes
biotechnology-listing-filing	e-bioseq.xml 6067 Bytes

EFS ID: 23108

FILE SIZE: 19031 Bytes

TIMESTAMP: Wed Feb 12 09:03:54 EST 2003

MESSAGE DIGEST: v04fy+oN3IWVu34Olik/qg==

DIGITAL CERTIFICATE HOLDER NAME: cn=Frank Christopher Eisenschenk, ou=Registered Attorneys

UPLOAD STATUS: You have successfully uploaded your submission to USPTO